Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Andrew P. Groves
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06896110CT.gov Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Astrocytoma, IDH-Mutant, Grade 4
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Andrew P. Groves | P1 | CC · 43 |
| Nivolumab | Andrew P. Groves | P2 | B |
| Safusidenib | Nuvation Bio Inc. | P3 | B |
| gi-102 | Mayo Clinic | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Pembrolizumab | Mayo Clinic | P2 | CCC |
| Ribociclib | St. Jude Children's Research Hospital | P1 | CC |
| Nivestim | St. Jude Children's Research Hospital | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
+7 more in the Astrocytoma, IDH-Mutant, Grade 4 cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Astrocytoma, IDH-Mutant, Grade 4. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-astrocytoma-idh-mutant-grade-4
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →